The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Open accessAbstract
BACKGROUND: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are used optimally. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of adalimumab (ADA), etanercept (ETN), infliximab (IFX), rituximab (RTX) and abatacept (ABT) when used in patients with RA who have tried conventional agents and have failed to improve after trying a first tumour necrosis factor (TNF) inhibitor. DATA SOURCES: A systematic review of primary studies was undertaken. Databases searched included the Cochrane Library, MEDLINE (Ovid) and EMBASE up to July 2009. STUDY SELECTION: Two reviewers assessed titles and abstracts of studies identified by the search strategy, obtained the full text of relevant papers and screened them against inclusion criteria. STUDY APPRAISAL: Data from included studies were extracted by one reviewer and checked by a second. The quality of included studies was assessed independently by two reviewers, with any disagreements resolved by discussion and consultation with a third reviewer if necessary. RESULTS: Thirty-five studies were included in the systematic review: five randomised controlled trials (RCTs), one comparative study, one controlled study and 28 uncontrolled studies. One RCT (REFLEX) demonstrated the effectiveness of RTX. At 6 months significantly more patients treated with RTX achieved American College of Rheumatology (ACR) 20 [relative risk (RR) = 2.85, 95% confidence interval (CI) 2.08 to 3.91] and ACR70 (RR = 12.14, 95% CI 2.96 to 49.86) compared with those treated with the placebo. Differences between groups in favour of RTX were observed at 6 months for mean change from baseline in Disease Activity Score 28 (DAS28) (mean difference -1.50, 95% CI -1.74 to -1.26) and mean change from baseline in Health Assessment Questionnaire (HAQ) score (mean difference -0.30, 95% CI -0.40 to -0.20). One RCT (ATTAIN) demonstrated the effectiveness of ABT. At 6 months significantly more patients treated with ABT achieved ACR20 (RR = 2.56, 95% CI 1.77 to 3.69) and ACR70 (RR = 6.70, 95% CI 1.62 to 27.80) compared with those treated with placebo. Significant differences between groups in favour of ABT were observed at 6 months for mean change from baseline in DAS28 score (mean difference -1.27, 95% CI -1.62 to -0.93) and mean change from baseline in HAQ score (mean difference -0.34). Twenty-eight uncontrolled studies observed improvement of effectiveness compared with before switching, in patients who switched to ADA, ETN or IFX after discontinued previous TNF inhibitor(s). Four studies were included in the systematic review of cost-effectiveness. Independent economic evaluation undertaken by the assessment group showed that compared with DMARDs, the incremental cost-effectiveness ratios (ICERs) were £34,300 [per quality-adjusted life-year (QALY)] for ADA, £38,800 for ETN, £36,200 for IFX, £21,200 for RTX and £38,600 for ABT. RTX dominates the TNF inhibitors and the ICER for ABT compared with RTX is over £100,000 (per QALY). LIMITATIONS: Paucity of evidence from RCTs for assessing the clinical effectiveness of TNF inhibitors and an absence of head-to-head trials comparing the five technologies. CONCLUSIONS: Evidence from RCTs suggests that RTX and ABT are more effective than supportive care. Data from observational studies suggest that the use of an alternative TNF inhibitor in patients who exhibit an inadequate response to a first TNF inhibitor may offer some benefit, but there remain uncertainties with regard to the magnitude of treatment effects and their cost-effectiveness. Future research should include head-to-head trials comparing the clinical effectiveness and cost-effectiveness of the technologies against each other and emerging biologics. FUNDING: This study was funded by the Health Technology Assessment programme of the National Institute for Health Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514020020010401 · Cited by 1,544
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,310
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Evidence that cytokines play a role in rheumatoid arthritis
Brennan, F. M., & McInnes, I. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36389 · Cited by 1,103
The Disease Activity Score and the EULAR Response Criteria
Fransen, J., & van Riel, P. L. C. M. (2009) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2009.10.001 · Cited by 877
Hurst, N. P., Kind, P., Ruta, D., Hunter, M., & Stubbings, A. (1997) · Rheumatology · doi:10.1093/rheumatology/36.5.551 · Cited by 826
Emery, P., Breedveld, F. C., Hall, S., Durez, P., Chang, D. J., Robertson, D., Singh, A., Pedersen, R. D., Koenig, A. S., & Freundlich, B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61000-4 · Cited by 821
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044354 · Cited by 786
Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
The Cochrane Database of Systematic Reviews – Issue 4 2008
Clarke, M. (2008) · Journal of Evidence-Based Medicine · doi:10.1111/j.1756-5391.2008.00009.x · Cited by 658
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
Symmons, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.7.793 · Cited by 646
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Predictors of infection in rheumatoid arthritis
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10529 · Cited by 560
Survival in rheumatoid arthritis: A population‐based analysis of trends over 40 years
Gabriel, S. E., Crowson, C. S., Kremers, H. M., Doran, M. F., Turesson, C., O'Fallon, W. M., & Matteson, E. L. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10705 · Cited by 516
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Fransen, J. (2004) · Rheumatology · doi:10.1093/rheumatology/keh297 · Cited by 484
Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gömör, B., Van den Bosch, F., Nordström, D., Bjørneboe, O., Dahl, R., et al. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.655 · Cited by 472
Heijde, D. M. F. M. V. D., Leeuwen, M. A. V., Riel, P. L. C. M. V., Koster, A. M., Hof, M. A. V., Rijswijk, M. H. V., & Putte, L. B. A. V. D. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350105 · Cited by 447
Meune, C., Touze, E., Trinquart, L., & Allanore, Y. (2009) · Rheumatology · doi:10.1093/rheumatology/kep252 · Cited by 431
Chen, Y.-F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., & Burls, A. (2006) · Health Technology Assessment · doi:10.3310/hta10420 · Cited by 406
Self-citationBritish Thoracic Society Standards of Care Committee
Blumenthal, S., Cooper, B. K., Davison, A., Elliott, M. W., Kinnear, W. J. M., Paton, R. W., Sawicka, E., & Turner, L. (2014) · Cited by 359
The Personal Social Services Research Unit
Hallam, A., Darton, R. A., McIntosh, E., & Netten, A. (1994) · Kent Academic Repository (University of Kent) · Cited by 342
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Wolfe, F., & Zwillich, S. H. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199806)41:6<1072::aid-art14>3.0.co;2-g · Cited by 291
Gomez-Reino, J. J., Carmona, L., & the BIOBADASER Group (2006) · Arthritis Research & Therapy · doi:10.1186/ar1881 · Cited by 289
Pincus, T., Marcum, S., & Callahan, L. F. (1992) · PubMed · Cited by 287
Jacoby, R. K., Jayson, M. I. V., & Cosh, J. A. (1973) · BMJ · doi:10.1136/bmj.2.5858.96 · Cited by 286
Rubbert-Roth, A., & Finckh, A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2666 · Cited by 266
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., & Dougados, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074773 · Cited by 264
Young, A., Dixey, J., Kulinskaya, E., Cox, N., Davies, P., Devlin, J., Emery, P., Gough, A., James, D., Prouse, P., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.335 · Cited by 260
A review of the MHC genetics of rheumatoid arthritis
Newton, J., Harney, S., Wordsworth, B., & Brown, M. (2004) · Genes & Immunity · doi:10.1038/sj.gene.6364045 · Cited by 258
Barrett, E. M. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1403 · Cited by 258
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
van der Kooij, S. M., Goekoop-Ruiterman, Y. P. M., de Vries-Bouwstra, J. K., Güler-Yüksel, M., Zwinderman, A. H., Kerstens, P. J. S. M., van der Lubbe, P. A. H. M., de Beus, W. M., Grillet, B. A. M., Ronday, H. K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092254 · Cited by 213
The costs of rheumatoid arthritis: an international long-term view
Pugner, K. M., Scott, D. I., Holmes, J. W., & Hieke, K. (2000) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(00)80017-7 · Cited by 211
Burmester, G. R., Xavier Mariette, A., Montecucco, C., Sáez, I. M., Malaise, M., Tzioufas, A. G., Bijlsma, J. W. J., Unnebrink, K., Kary, S., & Küpper, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066761 · Cited by 202
Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan
KOIKE, T., HARIGAI, M., INOKUMA, S., INOUE, K., ISHIGURO, N., RYU, J., TAKEUCHI, T., TANAKA, Y., YAMANAKA, H., FUJII, K., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080791 · Cited by 179
Bombardieri, S., Ruiz, A. A., Fardellone, P., Geusens, P., McKenna, F., Unnebrink, K., Oezer, U., Kary, S., Kupper, H., Burmester, G. R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem091 · Cited by 179
Kavanaugh, A., Rosengren, S., Lee, S. J., Hammaker, D., Firestein, G. S., Kalunian, K., Wei, N., & Boyle, D. L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074229 · Cited by 178
Puolakka, K., Kautiainen, H., Möttönen, T., Hannonen, P., Korpela, M., Julkunen, H., Luukkainen, R., Vuori, K., Paimela, L., Blåfield, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11436 · Cited by 177
Finckh, A., Simard, J. F., Gabay, C., & Guerne, P.-A. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045062 · Cited by 176
Economic consequences of the progression of rheumatoid arthritis in Sweden
Kobelt, G., Eberhardt, K., J�nsson, L., & J�nsson, B. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199902)42:2<347::aid-anr18>3.0.co;2-p · Cited by 169
Brouwer, W. B. F., van Exel, N. J. A., van de Berg, B., Dinant, H. J., Koopmanschap, M. A., & van den Bos, G. A. M. (2004) · Arthritis Care & Research · doi:10.1002/art.20528 · Cited by 168
Schiff, M. H., Pritchard, C., Huffstutter, J. E., Rodrı́guez-Valverde, V., Durez, P., Zhou, X., Li, T., Bahrt, K., Kelly, S., Bars, M. L., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099218 · Cited by 156
Nixon, R. M., Bansback, N. J., & Brennan, A. (2006) · Statistics in Medicine · doi:10.1002/sim.2624 · Cited by 156
Scott, D. L., Shipley, M. E., Dawson, A., Edwards, S. M., Symmons, D. P. M., & Woolf, A. D. (1998) · Rheumatology · doi:10.1093/rheumatology/37.5.546 · Cited by 152
Treatment continuation in patients receiving biological agents or conventional DMARD therapy
Zink, A., Listing, J., Kary, S., Ramlau, P., Stoyanova-Scholz, M., Babinsky, K., von Hinueber, U., Gromnica-Ihle, E., Wassenberg, S., Antoni, C., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031476 · Cited by 152
Estimating the incidence of rheumatoid arthritis: Trying to hit a moving target?
Wiles, N., Symmons, D. P. M., Harrison, B., Barrett, E. M., Barrett, J. H., Scott, D. G. I., & Silman, A. J. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1339::aid-anr6>3.0.co;2-y · Cited by 148
Miyasaka, N., & The CHANGE Study Investigators (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0045-0 · Cited by 144
Adalimumab for treating rheumatoid arthritis
Navarro-Sarabia, F., Ariza‐Ariza, R., Hernández‐Cruz, B., & Villanueva, I. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005113.pub2 · Cited by 140
Kobelt, G., Eberhardt, K., & Geborek, P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.010629 · Cited by 137
Infliximab for the treatment of rheumatoid arthritis
Blumenauer, B. B., Judd, M., Wells, G. A., Burls, A., Cranney, A., Hochberg, M. C., Tugwell, P., & Lopez-Olivo, M. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003785 · Cited by 133
Jones, G. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/keg036 · Cited by 131
Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
Wong, J. B., Singh, G., & Kavanaugh, A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01243-3 · Cited by 129
Barton, P. M., Jobanputra, P., Wilson, J. L., Bryan, S., & Burls, A. (2004) · Health Technology Assessment · doi:10.3310/hta8110 · Cited by 125
Self-citationLong-Term Outcomes in Rheumatoid Arthritis
Pincus, T. (1995) · Rheumatology · doi:10.1093/rheumatology/xxxiv.suppl_2.59 · Cited by 123
Bansback, N. J., Brennan, A., & Ghatnekar, O. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.027565 · Cited by 121
Symmons, D. P. M., Tricker, K. J., Roberts, C., Davies, L. M., Dawes, P. T., & Scott, D. (2005) · Health Technology Assessment · doi:10.3310/hta9340 · Cited by 120
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen, K. E., Hildebrand, J. P., Genovese, M. C., Cush, J. J., Patel, S. R., Cooley, D. A., Cohen, S. B., Gangnon, R. E., & Schiff, M. H. (2004) · PubMed · Cited by 117
Why do people with rheumatoid arthritis still die prematurely?
Gabriel, S. E. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.098038 · Cited by 116
Patient preferences for treatment of rheumatoid arthritis
Fraenkel, L., Bogardus, S. T., Concato, J., Felson, D. T., & Wittink, D. R. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019422 · Cited by 113
Fleischmann, R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24906 · Cited by 112
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout, W. B., Goekoop-Ruiterman, Y., Allaart, C., de Vries-Bouwstra, J., Hazes, J., Kerstens, P., van Zeben, D., Hulsmans, H. M. J., de Jonge-Bok, J. M., de Sonnaville, P. D., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24169 · Cited by 104
Genetic susceptibility to rheumatoid arthritis: An emerging picture
Barton, A. C., & Worthington, J. (2009) · Arthritis Care & Research · doi:10.1002/art.24672 · Cited by 104
Treharne, G. J., Lyons, A. C., Hale, E. D., Douglas, K. M. J., & Kitas, G. D. (2005) · Rheumatology · doi:10.1093/rheumatology/kei223 · Cited by 99
Quality of life measures: use and abuse
Scott, D. L., & Garrood, T. (2000) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2000.0106 · Cited by 94
Hoff, M., Kvien, T. K., Kälvesten, J., Elden, A. M. B., & Haugeberg, G. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091264 · Cited by 94
Mease, P. J., Revicki, D. A., Szechiński, J., Greenwald, M., Kivitz, A., Barile-Fabris, L. A., Kalsi, J., Eames, J. R., & Leirisalo‐Repo, M. (2008) · PubMed · Cited by 93
Cohen, G., Courvoisier, N., Cohen, J. D., Zaltni, S., Sany, J., & Combe, B. G. (2006) · PubMed · Cited by 86
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
Smolen, J. S., Aletaha, D., & Keystone, E. C. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21293 · Cited by 84
Doan, Q. V., Chiou, C., & Dubois, R. W. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.7.555 · Cited by 84
Prospects for B-cell-targeted therapy in autoimmune disease
Edwards, J., & Cambridge, G. (2004) · Rheumatology · doi:10.1093/rheumatology/keh446 · Cited by 84
PROPOSED MODIFICATION TO LARSEN'S SCORING METHODS FOR HAND AND WRIST RADIOGRAPHS
Scott, D. L., Houssien, D. A., & Laasonen, L. (1995) · Lara D. Veeken · doi:10.1093/rheumatology/34.1.56 · Cited by 82
van der Bijl, A. E., Breedveld, F. C., Antoni, C., Kalden, J. R., Kary, S., Burmester, G. R., Beckmann, C., Unnebrink, K., & Küpper, H. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0866-4 · Cited by 82
Ward, M. M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1467::aid-art243>3.0.co;2-6 · Cited by 81
Strand, V., Balbir‐Gurman, A., Pavelká, K., Emery, P., Li, N., Yin, M. H., Lehane, P. B., & Agarwal, S. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel358 · Cited by 75
Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity
Navarro-Cano, G., del Rincón, I., Pogosian, S. A., Roldán, J. F., & Escalante, A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11127 · Cited by 75
Hyrich, K. L., Lunt, M., Dixon, W. G., Watson, K. D., Symmons, D. P. M., & Register, O. B. O. T. B. B. (2008) · Rheumatology · doi:10.1093/rheumatology/ken127 · Cited by 75
A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis
Jobanputra, P. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keh003 · Cited by 75
Self-citationAng, H. T. S., & Helfgott, S. M. (2003) · PubMed · Cited by 73
Management of early rheumatoid arthritis
Dubey, S., & Gaffney, K. (2005) · Clinical Medicine · doi:10.7861/clinmedicine.5-3-211 · Cited by 69
A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
Nuijten, M. J. C., Engelfriet, P. M., Duijn, K., de Bruijn, G. S. J. T., Wierz, D., & Koopmanschap, M. A. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119100-00006 · Cited by 67
Weaver, A. L., Lautzenheiser, R. L., Schiff, M. H., Gibofsky, A., Perruquet, J. L., Luetkemeyer, J., Paulus, H. E., Xia, H. A., Leff, J. A., & on behalf of the RADIUS Investigators (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65510 · Cited by 67
Thurlings, R. M., Vos, K., Gerlag, D. M., & Tak, P. P. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24035 · Cited by 64
Labour force participation among patients with rheumatoid arthritis
Chorus, A. M. J., Miedema, H. S., Wevers, C. J., & van der Linden, S. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.7.549 · Cited by 64
Long-term outcomes of rheumatoid arthritis
Sokka, T. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832a2f02 · Cited by 62
Zintzaras, E., Dahabreh, I. J., Giannouli, S., Voulgarelis, M., & Moutsopoulos, H. Μ. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.007 · Cited by 61
Certolizumab pegol for the treatment of rheumatoid arthritis
Horton, S., Walsh, C. A., & Emery, P. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.645533 · Cited by 58
Minimal disease activity, remission, and the long‐term outcomes of rheumatoid arthritis
Wolfe, F., Rasker, J. J., Boers, M., Wells, G. A., & Michaud, K. D. (2007) · Arthritis Care & Research · doi:10.1002/art.22895 · Cited by 57
Kielhorn, A., Porter, D. R., Diamantopoulos, A., & Lewis, G. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802321683 · Cited by 56
Wiles, N., Scott, D. G. I., Barrett, E. M., Merry, P., Arié, E., Gaffney, K., Silman, A. J., & Symmons, D. P. M. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.10.956 · Cited by 53
Poór, G., & Strand, V. (2004) · Lara D. Veeken · doi:10.1093/rheumatology/keh168 · Cited by 44
Bokarewa, M. I., Lindholm, C., Zendjanchi, K., Nadali, M., & Tarkowski, A. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01995.x · Cited by 42
RUSSELL, A. S., Béresniak, A., Bessette, L., Haraoui, B. P., Rahman, P., Thorne, C., Maclean, R., & Dupont, D. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-1060-4 · Cited by 38
Heiberg, M. S., Rødevand, E., Mikkelsen, K., Kaufmann, C., Didriksen, A., Mowinckel, P., & Kvien, T. K. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.051540 · Cited by 38
Zhang, W., Bansback, N. J., Guh, D. P., Li, X., Nosyk, B., Marra, C. A., & Anis, A. H. (2008) · PubMed · Cited by 38
Garden of therapeutic delights: new targets in rheumatic diseases
Waldburger, J., & Firestein, G. S. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2556 · Cited by 37
Hamilton, J., McInnes, I. B., Thomson, E. A., Porter, D., Hunter, J. A., Madhok, R., & Capell, H. A. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.6.566 · Cited by 34
Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis
Blank, N., Max, R., Schiller, M. R., Briem, S. K., & Lorenz, H. M. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/ken491 · Cited by 31
Owczarczyk, K. M., Hellmann, M., Fliedner, G., Rohrs, T., Maizus, K., Passon, D., Hallek, M. J., & RUBBERT, A. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087023 · Cited by 25
Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis
Merkesdal, S., Ruof, J., Mittendorf, T., & Zeidler, H. K. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.9.1881 · Cited by 18
Tocilizumab for the treatment of rheumatoid arthritis
Rueda‐Gotor, J., González-Gay, M. Á., & Blanco, R. (2012) · Clinical Practice · doi:10.2217/cpr.12.21 · Cited by 15
Abatacept for the treatment of rheumatoid arthritis: A review
Kaine, J. (2007) · Current Therapeutic Research · doi:10.1016/j.curtheres.2007.12.001 · Cited by 12
Rituximab in patients with rheumatoid arthritis: systematic review
Brodszky, V., Czirják, L., Géher, P., Hodinka, L., Kárpáti, K., Péntek, M., Poór, G., Szekanecz, Z., & Gulàcsi, L. (2007) · Orvosi Hetilap · doi:10.1556/oh.2007.28080 · Cited by 8
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
Berney, S. M. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79111-9 · Cited by 8
Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic
Duftner, C., Dejaco, C., Larcher, H., et al. (2008) · Rheumatology International · doi:10.1007/s00296-008-0653-1 · Cited by 1
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
BYKERK, V. P., AKHAVAN, P., HAZLEWOOD, G. S., SCHIEIR, O., DOOLEY, A., HARAOUI, B., KHRAISHI, M., LECLERCQ, S. A., LÉGARÉ, J., MOSHER, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Non-alcoholic fatty liver disease
Sattar, N., Forrest, E., & Preiss, D. (2014) · BMJ · doi:10.1136/bmj.g4596 · Cited by 325
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
T cell migration in rheumatoid arthritis
Mellado, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00384 · Cited by 291
Metadata
- Authors
- Malottki, K., Barton, P., Tsourapas, A., Uthman, A., Liu, Z., Routh, K., Connock, M., Jobanputra, P., Moore, D., Fry-Smith, A., & Chen, Y.-F.
- Venue
- Health Technology Assessment
- Published
- 2011-03
- Volume
- 15
- Issue
- 14
- Pages
- 1-278
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2102987799
- Cited by
- 287
- References
- 115
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.